SCHEMBL5647833

SCHEMBL5647833

CCOCCC(=O)Nc1cc(Cl)ccc1O

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.72
▸ MEN1 O00255 6/20 0.65
▸ KMT2A Q03164 6/20 0.65
▸ HPGD P15428 1/20 0.65
▸ ALOX15 P16050 2/20 0.58
▸ MAPK1 P28482 2/20 0.58
▸ STAT3 P40763 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ GAA P10253 3/20 0.52
▸ KCNMA1 Q12791 4/20 0.52
▸ TSHR P16473 2/20 0.52
▸ LMNA P02545 1/20 0.52
▸ USP2 O75604 1/20 0.52
▸ TP53 P04637 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ ALDH1A1 P00352 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29721853 0.84 POLB (0.72) POLBMEN1KMT2AHPGDALOX15
SCHEMBL28734394 0.84 POLB (0.72) POLBMEN1KMT2AHPGDALOX15
SCHEMBL13166882 0.79 POLB (0.76) POLBMEN1KMT2AHPGDALOX15
SCHEMBL5144511 0.78 POLB (0.86) POLBMEN1KMT2AHPGDALOX15
SCHEMBL7257110 0.77 MEN1 (0.72) POLBMEN1KMT2AHPGDALOX15
SCHEMBL7719057 0.77 POLB (0.71) POLBMEN1KMT2AHPGDALOX15
SCHEMBL30612630 0.76 POLB (0.75) POLBMEN1KMT2AHPGDALOX15
SCHEMBL247350 0.76 POLB (0.75) POLBMEN1KMT2AHPGDALOX15
SCHEMBL7718043 0.75 POLB (0.69) POLBMEN1KMT2AHPGDALOX15
SCHEMBL3046406 0.75 POLB (0.69) POLBMEN1KMT2AHPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138546-B2 N-(2-chlorophenyl) hydroxy- or alkoxyalkanamides, e.g.,N-(5-Chloro-2-hydroxyphenyl)-2-(2-hydroxyphenoxy)acetamid e); can deliver a broad range of active agents by various routes. EMISPHERE TECHNOLOGIES, INC. (US) 2006-11-21 — — US disclosed
US-20030216287-A1 Compounds and compositions for delivering active agents NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2003-11-20 — — US disclosed
EP-1317412-A1 COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS Emisphere Technologies, Inc. (US) 2003-06-11 — — EP disclosed
WO-2002016309-A1 COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2002-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216287-A1 Compounds and compositions for delivering active agents SERPINB1, ELANE, MMP8 POLB 985/4885MEN1 1531/4885KMT2A 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback